NCT01267955 2026-03-18
Vismodegib in Treating Patients With Advanced Chondrosarcomas
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
4 trialsNCT00878163 2026-03-17
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01878617 2025-11-13
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT06357988 2025-10-20
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
National Cancer Institute (NCI)
Phase 2 Active not recruiting